Horizon Therapeutics Plc

HZNP

$114.75

+56.8% (1 year change)

Market Cap

$26.3 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$66.41 - $116.80

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

50.77x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $26.3 Billion
Enterprise Value $28.1 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +56.8%
52-Week High $116.80
52-Week Low $66.41
Beta 1.02
Outstanding Shares 226 Million
Avg 30 Day Volume 1.14 Million

Valuation

P/E Ratio 50.77
PEG -17.06
Earnings per Share $2.21
Price to Sales Ratio 10.43
Price to Book Ratio 6.38
Revenue to Enterprise Value 10.98
EBIT to Enterprise Value 62.02
Total Debt to Enterprise Value 0.09
Debt to Equity 0.63

Profitability

Revenue $2.56 Billion
Gross Profit $1.94 Billion
EBIT $453 Million
Net Income $518 Million
Profit Margin 20.27%
Quarterly Earnings Growth (YoY) -297.6%
Return on Equity 12.72%
Return on Assets 6.31%
Return on Invested Capital 6.15%

Insider trades

No purchases

240,668 shares sold (16 transactions)

No purchases

193,982 shares sold (5 transactions)

No purchases

105,100 shares sold (4 transactions)

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

Similar stocks

AMGEN Inc.
Astrazeneca plc - ADR
Radius Health Inc.
Pfizer Inc.
Dr. Reddy`s Laboratories Ltd. - ADR
Merck & Co Inc

News

Horizon Therapeutics plc: MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA (pegloticase injection) with Methotrexate

Horizon Therapeutics plc: MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA (pegloticase injection) with Methotrexate

-- Horizon expects to file a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration in first quarter of 2022 based on significant improvement in response rate

FinanzNachrichten FinanzNachrichten, 3 days ago
Horizon Therapeutics Public (NASDAQ:HZNP) Sets New 1-Year High at $116.80

Horizon Therapeutics Public (NASDAQ:HZNP) Sets New 1-Year High at $116.80

Horizon Therapeutics Public Limited (NASDAQ:HZNP) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $116.80 and last traded at $116.46, with a volume of 82184 s...

 Dakota Financial News Dakota Financial News, 5 days ago
Horizon Therapeutics Public Limited (NASDAQ:HZNP) Expected to Announce Quarterly Sales of $980.31 Million

Horizon Therapeutics Public Limited (NASDAQ:HZNP) Expected to Announce Quarterly Sales of $980.31 Million

Brokerages predict that Horizon Therapeutics Public Limited (NASDAQ:HZNP) will announce $980.31 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for...

Transcript Daily Transcript Daily, 5 days ago